Highlights From AACR IO 2026: Breaching the Tumor Microenvironment Fortress With New CAR T and Chimeras
Three innovative studies at AACR IO 2026 presented new ways for CAR T cells and antibody-lectin chimeras to tackle...
Three innovative studies at AACR IO 2026 presented new ways for CAR T cells and antibody-lectin chimeras to tackle...
A year-end review of some of the new cancer treatments, exciting breakthroughs, and insights into cancer's development that emerged...
At SABCS 2025, studies show some patients with early-stage breast cancer can skip steps like SLNB or MRI without...
In clinical trials presented at SABCS, a mobile health tool and acupuncture helped to improve breast cancer survivors' quality...
Amid the debate over menopausal hormone therapy and cancer risk, researchers at SABCS provided some clarity for women with...
Throughout the years, SABCS has shown how tucatinib has progressed into a potential frontline therapy for HER2-positive breast cancer.
New insights into the neurologic and physiologic impact of chronic stress on ovarian cancer were presented at two recent...
Experts discussed challenges and opportunities for dose optimization of cancer treatments at the 2025 AACR-Industry Roundtable.
The inaugural AACR Pediatric Cancer Progress Report details advances in treating children and adolescents with cancer and remaining gaps...
Steve Schneible covered the AACR Philadelphia Marathon Weekend live, including updates from his own participation in the half marathon.
In November, the AACR’s journal editors highlighted studies on sucralose limiting immunotherapy, benefits of caloric restriction, and more.